https://orcid.org/0000-0001-5071-9257
Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Kehong Yang, Susan Hua, Wenting Wei, Congyan Yang, Xinhai Zhu & Shu Chuen Li. (2023) Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China. Journal of Medical Economics 26:1, pages 1424-1431.
Read now
Read now
Tara Cowling, Ransi Nayakarathna, Allison L. Wills, Dipti Tankala, Nancy Paul Roc & Stephane Barakat. (2023) Early access for innovative oncology medicines: a different story in each nation. Journal of Medical Economics 26:1, pages 944-953.
Read now
Read now
Hala H. Halawah, Nimer S. Alkhatib, Abdulaali R. Almutairi, Mohammad Saleh, Shiraz S. Halloush, Omar Rashdan, Lama Masadh, Osama H. Abusara & Ivo Abraham. (2023) Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan. Journal of Medical Economics 26:1, pages 835-842.
Read now
Read now
Luca Boscolo Bielo, Dario Trapani & Giuseppe Curigliano. (2023) Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer. Expert Opinion on Pharmacotherapy 24:7, pages 789-801.
Read now
Read now
Panagiotis Petrou. (2023) Budget impact analysis of daratumumab for light-chain amyloidosis in Cyprus. Expert Review of Pharmacoeconomics & Outcomes Research 23:3, pages 345-351.
Read now
Read now
Shiraz Halloush, Abdullah A. Alhifany, Nimer S. Alkhatib, Abdel Qader Al Bawab, Batool AL-Qawasmeh, Esra’a Al Shawakri & Jim Koeller. (2022) Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting. Current Medical Research and Opinion 38:4, pages 571-577.
Read now
Read now
Brian Godman, Andrew Hill, Steven Simoens, Gisbert Selke, Iva Selke Krulichová, Carolina Zampirolli Dias, Antony P Martin, Wija Oortwijn, Angela Timoney, Lars L Gustafsson, Luka Voncina, Hye-Young Kwon, Jolanta Gulbinovic, Dzintars Gotham, Janet Wale, Wânia Cristina Da Silva, Tomasz Bochenek, Eleonora Allocati, Amanj Kurdi, Olayinka O. Ogunleye, Johanna C Meyer, Iris Hoxha, Admir Malaj, Christian Hierländer, Robert Sauermann, Wouter Hamelinck, Guenka Petrova, Ott Laius, Irene Langner, John Yfantopoulos, Roberta Joppi, Arianit Jakupi, Ieva Greiciute-Kuprijanov, Patricia Vella Bonanno, Jf (Hans) Piepenbrink, Vincent de Valk, Magdalene Wladysiuk, Vanda Marković-Peković, Ileana Mardare, Jurij Fürst, Dominik Tomek, Mercè Obach Cortadellas, Corinne Zara, Caridad Pontes, Stuart McTaggart, Tracey-Lea Laba, Øyvind Melien, Durhane Wong-Rieger, SeungJin Bae & Ruaraidh Hill. (2021) Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Review of Pharmacoeconomics & Outcomes Research 21:4, pages 527-540.
Read now
Read now
Panagiotis Petrou. (2021) Budget impact analysis: can we afford the added value?. Journal of Medical Economics 24:1, pages 487-489.
Read now
Read now
Articles from other publishers (2)
Shiraz Halloush, Nimer S. Alkhatib, Abdulaali R. Almutairi, Mathias Calamia, Hala Halawah, Mavis Obeng-Kusi, Martin Hoyle, Omar Rashdan, Jim Koeller & Ivo Abraham. (2023) Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective. Annals of Pharmacotherapy, pages 106002802211468.
Crossref
Crossref
Ildikó Ádám, Marcelien Callenbach, Bertalan Németh, Rick A. Vreman, Cecilia Tollin, Johan Pontén, Dalia Dawoud, Jamie Elvidge, Nick Crabb, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Anke Pisters-van Roy, Áron Vincziczki, Emad Almomani, Maja Vajagic, Z. Gulsen Oner, Mirna Matni, Jurij Fürst, Rabia Kahveci, Wim G. Goettsch & Zoltán Kaló. (2022) Outcome-based reimbursement in Central-Eastern Europe and Middle-East. Frontiers in Medicine 9.
Crossref
Crossref